Mankind Pharma Limited (BOM:543904)
India · Delayed Price · Currency is INR 2,417.35
+12.40 (0.52%)
At close: Jun 19, 2026
Mankind Pharma Stock Forecast
Stock Price Forecast
According to 20 analysts polled by S&P Global, Mankind Pharma stock has a consensus rating of "Buy" and an average price target of ₹2,653. The average 1-year stock price forecast is 9.76% higher than the current stock price, while the lowest is ₹1,990 (-17.68%) and the highest is ₹3,100 (+28.24%).
Price Target: ₹2,653 (+9.76%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Mankind Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 8 | 8 | 8 | 7 | 6 |
| Buy | 6 | 7 | 8 | 8 | 8 | 9 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 2 | 2 | 2 | 3 | 3 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 18 | 19 | 20 | 20 | 20 | 20 |
Financial Forecast
Revenue This Year
159.87B
from 142.78B
Increased by 11.97%
Revenue Next Year
177.74B
from 159.87B
Increased by 11.17%
EPS This Year
57.38
from 51.96
Increased by 10.43%
EPS Next Year
71.70
from 57.38
Increased by 24.96%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 164.9B | ||
| Avg | 159.9B | ||
| Low | 157.5B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 15.5% | ||
| Avg | 12.0% | ||
| Low | 10.3% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 62.80 | ||
| Avg | 57.38 | ||
| Low | 51.70 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 20.9% | ||
| Avg | 10.4% | ||
| Low | -0.5% |